Follow
Cancer Therapeutics
Cancer Therapeutics: Cancer is often treated by surgery, chemotherapy, radiation therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy), hormonal therapy, and synthetic lethality. The choice of therapy depends upon the stage of the disease, and the location and grade of the tumor, as well as the patient's general status. Many clinical trial cancer treatments are also under development.
JAN 01, 2020 | 6:00 AM
“The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo...
JAN 01, 2020 | 6:00 AM
With an increasing push to improve safety, efficacy, and efficiency throughout the drug development pipeline, researchers are evermore looking to improve the predictive capacity of their in...
DEC 17, 2019 | 9:00 AM
DATE: December 17, 2019TIME: 9:00am PST, 12:00pm EST Purpose: Liver x receptors (LXRs) are hypothesized to serve as a link between lipid metabolism and inflammation by prom...
DEC 05, 2019 | 9:00 AM
DATE: December 5, 2019TIME: 9:00am PST, 12:00pm EST Characterization of the spatial distribution and abundance of proteins and mRNAs with morphological context within tissues e...
NOV 21, 2019 | 9:00 AM
DATE: November 21, 2019TIME: 9:00am PST, 12:00pm EST Multiple Myeloma is a disease of terminally differentiated plasma cells with the massive production of monoclonal immunoglobu...
NOV 21, 2019 | 8:00 AM
DATE: November 21, 2019TIME: 8:00am PSTA complex interaction among heterogenous immune and tumor cells within the tumorous tissue not only influences tumor progression, but can also sha...
NOV 14, 2019 | 9:00 AM
Central to the diagnosis and management of patients with diabetes mellitus is the measurement of hemoglobin A1c (HbA1c). Major studies have defined the therapeutic targets of HbA1c in order...
OCT 31, 2019 | 9:00 AM
DATE: October 31, 2019TIME: 9:00am PDT, 12:00pm EDT INTRODUCTION: A major limitation for the development of 3D engineered tissues is the absence of viable and perfusable...
OCT 24, 2019 | 12:00 PM
The emergence of medicinal hemp represents a new frontier in medicine; one which has tremendous potential for patients struggling with a wide array of illnesses. However, in order to fully ca...
OCT 10, 2019 | 1:30 PM
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
OCT 10, 2019 | 12:00 PM
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
OCT 10, 2019 | 10:30 AM
Accumulation of structural variations (SVs) across the genome is a known trigger factor for oncogenesis. Structural mutations have been clearly implicated in a number of cancers, most notably...
